HDCN Abstract:  ASN Annual Meeting -- Philadelphia  

Eckardt KU, Macdougall I, Locatelli F, Tsakiris D, et al

Effects of epoetin beta on left ventricular mass in patients with chronic kidney disease: Echocardiographic results from the CREATE study.

ASN Annual Meeting -- Philadelphia
J Am Soc Nephrol (Nov) 16:37A 2005

Left ventricular hypertrophy (LVH) is an independent predictor of cardiovascular risk in patients with chronic kidney disease (CKD). The Cardiovascular risk Reduction by Early Anemia Treatment with Epoetin beta (CREATE) study included assessment of anemia treatment with epoetin beta on LVH. Patients (stage 34 CKD) with mild-to- moderate anemia (Hb 1112.5 g/dl) were randomized to receive once-weekly subcutaneous epoetin beta (starting dose 2000 units/week) as required to achieve Hb of 1315 g/dl (Group 1) or to maintain Hb 10.511.5 g/dl (Group 2). LV mass index (LVMI) was assessed echocardiographically at baseline and annually, mean observation period 2.5 yrs. At baseline and study end, there were no significant differences between the two study groups. LVMI was maintained stable over the observation period (baseline: 12035 and 11834 g/m2; follow-up 11721 and 11229 g/m2, Groups 1 and 2, respectively). When grouped by baseline LVMI range, there were significant reductions in LVMI after 1 and 2 yrs (Table). In conclusion, epoetin beta treatment prevented further progression of LVH in CKD patients with mild-to- moderate anemia. In those with LVH at baseline, anemia treatment resulted in a significant decrease in LVMI.

LVMI rangeBaselineYr 1Yr 2p- value
Group 1100-130, n=81114.08.9108.322.2110.322.0<0.05a
130-160, n=50142.47.5134.231.0121.928.7<0.01c
>160, n=25189.028.2172.241.8174.742.6<0.01b
Group 2100-130, n=90113.88.7110.6 23.9105.823.3<0.01b
130-160, n=45140.78.6136.528.0124.128.6<0.01b
>160, n=27186.223.7157.332.5162.938.7<0.05c
Baseline vs aYr 1, bYr 2 and cYr 1 and 2

Disclosure - Grant/Research Support: Genzyme; Consultant: F Hoffman La Roche, Amgen, Genzyme; Scientific Advisor: F Hoffmann La Roche, Amgen

© Copyright 2005-2006, American Society of Nephrology. Reproduced with permission.
Until September of 2006, all ASN abstracts from the 2005 Annual Meeting are available at this link.

Disclaimer: Abstracts often have errors, both typographical and otherwise. This posting is an electronic translation of submitted abstracts which has not been verified against the original submitted abstract nor with the authors for accuracy. As a result, there may be errors, especially with regard to drug doses, but not limited to these. Abstracts undergo only limited review, and data often are changed as a result of the peer review process, so their reliability is less than manuscripts published in peer-reviewed journals. In using these summaries, you are agreeing that you are aware of these limitations.

The materials are provided on an as-is basis without any warranty of any kind, either express or implied. In addition to errors, the information presented may be incomplete or outdated. The information contained is not intended nor recommended as a substitute for professional medical advice. You are advised to check the appropriate medical literature and the product information currently provided by the manufacturer of each device to be used or drug to be administered to verify the dosage, the method and duration of administration, or contraindications. It is the responsibility of the treating physician or other health care professional, relying on independent experience and knowledge of the patient, to determine drug, disease, and the best treatment for the patient.

To the fullest extent permitted by law, HDCN, ASN and their affiliates and suppliers disclaim all warranties, express or implied, including, but not limited to, any warranty of merchantability, non- infringement or fitness for a particular purpose.

In no event shall HDCN, ASN, or their affiliates or suppliers be liable for any damages whatsoever (including, but not limited to, direct, indirect, incidental, consequential, punitive or exemplary damages, or any damages for loss of profits, use, data, goodwill or other intangibles) arising from or in any way relating to these terms, the materials, or any information, goods or services obtained from or referred to in the materials, whether based on warranty, contract, tort (including, but not limited to, negligence), or any other legal theory, and whether or not any or all of the limited entities is advised of the possibility of such damages.